AmMax Bio

Executive Summary

AmMax Bio is a private, San Francisco-based biotechnology company focused on developing innovative antibody and biologic therapies for oncology. The company's lead program, AMB-066, leverages robust translational expertise and is supported by compelling preclinical data as well as a well-established safety profile from six completed clinical trials. Currently in Phase 2 development, AMB-066 targets a key pathway in solid tumors, and ongoing studies aim to establish efficacy in specific patient populations. AmMax's pipeline prioritizes assets with validated mechanisms and strong biomarker strategies, positioning the company to address high-unmet-need indications. With a seasoned management team and a focus on data-driven development, AmMax is poised to generate significant clinical data in the near term. The company's private status and early-stage pipeline imply higher risk but also potential for substantial upside upon positive trial readouts or strategic partnerships.

Upcoming Catalysts (preview)

• Q3 2026Phase 2 Interim Data Readout for AMB-06645% success
• Q4 2026Series B Financing or Strategic Partnership60% success
• Q2 2026FDA Fast Track or Orphan Drug Designation for AMB-06635% success